HOMOTAURINE INVESTIGATIONAL SUMMARY
|
|
- Lorena O’Neal’
- 5 years ago
- Views:
Transcription
1 HOMOTAURINE INVESTIGATIONAL SUMMARY
2 Amyloid Precursor Protein (brain) Amyloid Aß Amyloid fibril Amyloid plaque action mechanism Aisen PS. Presented at: 9th International Geneva Springfield Symposium on Advances in Therapy. April 26. inhibits formation of toxic amyloid fibrils in vitro Brain cell damage/death Brain volume loss Memory Loss & Cognitive Decline Amyloid Aß protects against Aß-Induced Neurotoxicity in mouse hippocampal cells Aß 48 hours 24-hour incubation Amyloid Aß + Aisen PS. Presented at: 9th International Geneva Springfield Symposium on Advances in Therapy. April 26. Control Neurotoxicity Aß + 2 Propidium iodide staining (shows dead cells: red coloration)
3 Scapagnini G. Presented at: GerontoNet Symposium Roma Clinical Trials in the frail elderly person. November 29. GABA-Dependent Neuroprotective Effect of Apoptotic agents Ischemic stress Trophic deprivation MPTP MK81 STS GABA A Caspase 3/7 & 9 Neurotoxicity Scapagnini G. Presented at: GerontoNet Symposium Roma Clinical Trials in the frail elderly person. November 29. GABA-Independent Neuroprotective Activity of ERK1/2 Aß Aß action mechanism Biochemical analysis Western blot DNA fragmentation/condensation Hoechst assay Neurotoxicity 3
4 Gervais F. et al. Neurobiol Aging 27; 28(4): penetrates into the brain mouse study Plasma (1 mg/kg) Plasma (5 mg/kg) Brain (1 mg/kg) Brain (5 mg/kg) Mean (± SD) Brain and Plasma Concentration (µg eq/g) Time (h) preclinical Gervais F. et al. Neurobiol Aging 27; 28(4): Control (untreated) prevents Aß-Induced inhibition of Long-Term Potentiation (LTP) acsf Aß 1-42 Aß HT (25 µm) Aß HT (1 µm) (1 mg/kg/day) (8 weeks of treatment) Gervais F. et al. Neurobiol Aging 27; 28(4): Normalised fepsp amplitude LTP Induction reduces Amyloid deposition in happ transgenic mouse brain Rat Hippocampal Slice Time (min) P<.1 4 PRECLINICAL TOXICOLOGY/ PHARMACOKINETICS Safe & well tolerated upon chronic exposure (39 wks) Not mutagenic No effect on liver enzyme activity (CYP 45)
5 16 CLINICAL TRIALS INVOLVING > 2 SUBJECTS Studies N Population Duration Endpoints 1 Phase I 288 Healthy 7-1 days Safety / PK Phase II 58 3 months Amyloid Aβ CSF level Phase II Extension months Phase II Phase III North America (NA) Phase III NA Extension Phase III Europe 1 clinical Phase I studies 288 healthy subjects (74 elderly) exposed Safe & well tolerated in young & elderly No serious adverse events reported No effect on cardiac conduction (QTc) CSF Aß42 (pg/ml) change from baseline Aisen PS et al. Neurology 26; 67(1): Phase II: Dose-Dependent Decrease of Aß 42 Cerebrospinal (CSF) Levels in AD Patients Cerebral Amyloid Angiopathy 3 months 18 months 12 months 18 months Phase I: Safety Results Estimated fit with 95% confidence limits Neurological function Brain volume Brain volume r =.36 p =.41 clinical studies dose (mg BID) 5
6 clinical studies 6 NORTH AMERICAN PHASE III STUDY DESIGN 1,52 mild to moderate AD patients were given either placebo or homotaurine for 18 months /placebo administered as add-on to AChE inhibitors ± memantine was tested using the standard, validated ADAS-cog test every 3 months Brain Volume (hippocampus) was measured at baseline and after 18 months of treatment in a subset of patients Saumier D. et al. Domain-specific effects of tramiprosate in patients with mild-to-moderate s disease: ADAS-cog Subscale results from the Alphase study. J. Nutrition Health Aging 29; 13(9): ADAS-cog subtest Remembering Test Instructions Language Comprehension Spoken Language Ability Ideational Praxis Change in scores in 1 yr (1 mg homotaurine vs placebo) 66.7% better* 38.9% better 4.% better 33.% better *Statistically significant Gauthier S. et al. Effect of tramiprosate in patients with mild-to-moderate s disease: Exploratory analyses of the MRI subgroup of the Alphase study. J. Nutrition Health Aging 29; 13(6): Mean (95% Confidence Intervals) Effects of on specific types of cognitive performance Adjusted Least Square Mean Change in Hippocampal Volume From Baseline to Final Assessment 68% difference p-value =.35 Placebo 1 mg 15 mg Treatment Group Adjusted by Mixed Effects Model preserved by 68% brain volume vs control in ad patients
7 Sampalis J. Presented at: GerontoNet Symposium Roma Clinical Trials in the frail elderly person. November 29. reduces significantly cognitive decline in ad patients - APOE4+ Overall treatment effect: P =.25 Change in ADAS-Cog (Mean) (82%) P = (57%) P =.118 Placebo 1 MG BID 15 MG BID weeks -2.3 (35%) P = (32%) P = (22%) P = (27%) P = (21%) P = (12%) P =.265 Adjusted by Mixed Effects Repeated Measures Model PUBLICATIONS: STUDIES PERFORMED WITH HOMOTAURINE 1. Martineau E. et al. Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS. J Am Soc Mass Spectrom. 21 Sep;21(9): Epub 21 May Shitaka Y. et al. Progress in the development of anti amyloid drugs for treatment of s disease. Nippon Yakurigaku Zasshi. 21 Jul; 136(1): Gauthier S. et al. Effect of tramiprosate in patients with mild-to-moderate s disease: Exploratory analyses of the MRI subgroup of the Alphase study. J. Nutrition Health Aging 29; 13(6): Saumier D. et al. Domain-specific effects of tramiprosate in patients with mild-to-moderate s disease: ADAS-cog Subscale results from the Alphase study. J. Nutrition Health Aging 29; 13(9): Gervais F. et al. Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 27; 28(4): Aisen PS. et al. A Phase II study targeting Amyloid ß with 3APS in mildto-moderate Disease. Neurology 26; 67, Greenberg SM. et al. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Disease and Associated Disorders 26; 2(4): Kisilevsky R. et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for s disease. Nature Med 1995; 1: Aisen P. et al. Tramiprosate in mild-to-moderate s disease: a randomized, double-blind, placebo controlled, multicenter study. Submitted to J. Amer. Geriatry and Gerontology (under review). clinical studies 7
November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationTargeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1
Targeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1 ADC Directors Meeting, April 18 th 2015 Frank M. Longo, Stanford
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationJ. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008
Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer s Disease J. Thomas Megerian, MD, PhD Executive Director, Clinical Research March 28, 2008 EPIX: GPCR Focused Drug Discovery
More informationTramiprosate in mild-to-moderate Alzheimer s disease a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
Clinical research Tramiprosate in mild-to-moderate Alzheimer s disease a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Paul S. Aisen 1, Serge Gauthier 2, Steven H.
More informationTropisetron: A promising drug to prevent Alzheimer s disease
Expert Opinion on Therapeutic Targets (Editorial) Tropisetron: A promising drug to prevent Alzheimer s disease Short title: Tropisetron for Alzheimer s disease Word count of the manuscript: 1324 words
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationTOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION. Paul S. Aisen, MD Department of Neurosciences University of California, San Diego
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION Paul S. Aisen, MD Department of Neurosciences University of California, San Diego Brief History of AD Therapeutics 1906: Dr. Alois Alzheimer
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationEXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease
EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationConcept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationPhase III Clinical Trial. Randomization, Blinding and Baseline Assessment. Chi-hong Tseng, PhD Statistics Core, Department of Medicine
Phase III Clinical Trial Randomization, Blinding and Baseline Assessment Chi-hong Tseng, PhD Statistics Core, Department of Medicine Reference Clinical Trials: A Practical Approach. Pocock SJ. Wiley, Chichester,
More informationBiogen, Cambridge, MA, USA; 2 Cytel, Cambridge, MA, USA; 3 Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer s Disease Samantha Budd Haeberlein, PhD 1, Sarah Gheuens,
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationNeuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationSupplementary Fig. 1
PDK1-dependent quenching of TACE shedding activity in prion and Alzheimer s diseases Mathéa Pietri, Caroline Dakowski, Samia Hannaoui, Aurélie Alleaume-Butaux, Julia Hernandez-Rapp, Audrey Ragagnin, Sophie
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationNovel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease
Novel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease Prof. Christian Hölscher, PhD Biomed and Life Sciences Faculty of Health and Medicine Lancaster University, UK Alzheimer
More informationAAIC 2018, Chicago, Illinois, US. July 22, 2018
24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2
ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2 SUPPLEMENTARY FIGURES AND TABLE Supplementary Figure S1: Conservation of the D domain throughout evolution. Alignment of TRF2 sequences
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationThe Potential Effect of Caffeine and Nicotine Co-administration on the Induction of Alzheimer s disease
The Potential Effect of Caffeine and Nicotine Co-administration on the Induction of Alzheimer s disease Azza A Ali *, Hebatalla I Ahmed * Hanan A Abd El-Samea ** Ebtehal El-Demerdash *** * Pharmacology
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationLead Neurotoxicity. Current Status and New Approaches. Stephen M. Lasley, Ph.D.
Lead Neurotoxicity Current Status and New Approaches Stephen M. Lasley, Ph.D. Cancer Biology and Pharmacology Univ. of Illinois College of Medicine Peoria, Illinois Sources of Lead Exposure Pb-based based
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationTAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, C. Lai, K. Duong-Polk, A. Tjitro, D.C. Ince,
More informationPage 39 of 44. 8h LTA & AT h PepG & AT h LTA
Page 39 of 44 Fig. S1 A: B: C: D: 8h LTA 8h LTA & AT7519 E: F: 8h PepG G: 8h PepG & AT7519 Fig. S1. AT7519 overrides the survival effects of lipoteichoic acid (LTA) and peptidoglycan (PepG). (A) Human
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More information- 1 - Cell types Monocytes THP-1 cells Macrophages. LPS Treatment time (Hour) IL-6 level (pg/ml)
Supplementary Table ST1: The dynamic effect of LPS on IL-6 production in monocytes and THP-1 cells after GdA treatment. Monocytes, THP-1 cells and macrophages (5x10 5 ) were incubated with 10 μg/ml of
More informationTable S1. New colony formation 7 days after stimulation with doxo and VCR in JURKAT cells
Table S1. New colony formation 7 days after stimulation with and in JURKAT cells drug co + number of colonies 7±14 4±7 48±11 JURKAT cells were stimulated and analyzed as in Table 1. Drug concentrations
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationEuropean Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationFlicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease
Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease Mojtaba Golzan (Research Fellow-Alzheimer s Australia) Department of Clinical Medicine, Macquarie University Ms. Dana Georgevsky
More informationDIET, AGING, and MIND. Neal G. Simon, Ph. D. Dept. of Biological Sciences Lehigh University
DIET, AGING, and MIND Neal G. Simon, Ph. D. Dept. of Biological Sciences Lehigh University Outline: Diet, Aging, and Mind 1. Brain Changes in Aging 2. Dementias 3. Dietary Interventions: DHEA and Soy 4.
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationAT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationMary ET Boyle, Ph. D. Department of Cognitive Science UCSD
? Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Christian S Lobsiger & Don W Cleveland (2007) Nature Neuroscience 10, 1355-1360 Astrocytes: interlinked gatekeepers of glutamate astrocytes
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationSafety, Tolerability and Target Engagement Demonstrated in Phase 1 Study of LRRK2 Inhibitor DNL201 in Healthy Young and Elderly Adults
Safety, Tolerability and Target Engagement Demonstrated in Phase 1 Study of LRRK2 Inhibitor DNL201 in Healthy Young and Elderly Adults MJFF Parkinson s Disease Therapeutics Conference October 25, 2018
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationWnt Signaling Pathway and AD
Center for Cell Regulation and Pathology Joaquín V. Luco (CRCP), Millennium Institute (MIFAB) Center for Aging and Regeneration (CARE). Wnt Signaling Pathway and AD Nibaldo C. Inestrosa European Union
More informationRational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia
Spectrum of AD Rational Drug Used For Cognitive Treatment of Alzheimer Disease And Related Dementia Assoc.Prof. Vorapun Senanarong, BSc., MD., DTM&H(London), FRCP(London) MCI, mild cognitive Impairment
More informationWhat We Can Do To Prevent or Reduce the Risk for Dementia
What We Can Do To Prevent or Reduce the Risk for Dementia Colloquium on Health and Wellness October 10 th, 2018 Frank M. Longo, MD, PhD Professor and Chair Department of Neurology and Neurological Sciences
More informationInfiltrative Brain Mass Due To Progressive Alzheimer's Disease
Article ID: WMC00505 2046-1690 Infiltrative Brain Mass Due To Progressive Alzheimer's Disease Corresponding Author: Dr. Mark Lyons, Associate Professor, Mayo Clinic Arizona, 85054 - United States of America
More informationProthena Corporation plc Overview
November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ Forward-Looking Statements This presentation contains forward-looking statements. These
More informationThe Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461
The Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461 1 TABLE OF CONTENTS Profile Summary Mechanism of Action Clinical Study Results Pharmacologic Profile Safety and Toxicity
More informationResearch Development: Bedside to Bench and Back
Research Development: Bedside to Bench and Back Matt Bellizzi, MD PhD Department of Neurology University of Rochester School of Medicine and Dentistry Rochester, NY "I can walk down the hall just fine,
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationVascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center
Vascular Dementia Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center none Disclosures Objectives To review the definition of Vascular Cognitive Impairment (VCI);
More informationOutcome measures in neuroscience clinical trials
Neuroscience TM Outcome measures in neuroscience clinical trials Jang-Ho Cha, Head, Translational Medicine Neuroscience Novartis Institute for BioMedical Research February 2017 Outline What is our problem?
More informationSignificant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy
Paterson, Abdi 1 Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy Ross W Paterson MRCP 1 *, Zeinab Abdi MRCP 1 *, Amanda Haines RMN 1, Jonathan M
More informationInternational Journal of Pharmaceutical and Medical Research Volume 3 Issue 4 August 2015 Website: ISSN:
International Journal of Pharmaceutical and Medical Research Volume 3 Issue 4 August 2015 Website: www.woarjournals.org/ijpmr ISSN: 2348-0262 Evaluation of Visual Field and Perg Parameters of Glaucomatous
More informationAdaptive Design in CIAS
Adaptive Design in CIAS or If you don t know where you re going, any road will get you there Michael Sand, PhD, MPH Senior Clinical Program Leader, CNS Boehringer Ingelheim Disclosures I m an employee
More informationThere is a consensus that the pathology
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 5, Number 2, 2018 Review Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts,
More informationCorporate Medical Policy Genetic Testing for Alzheimer s Disease
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
More informationSUPPLEMENTARY INFORMATION
Figure S1 Induction of non-apoptotic death of SV40-transformed and primary DKO MEFs, and DKO thymocytes. (A-F) STS-induced non-apoptotic death of DKO MEF. (A, B) Reduced viability of DKO MEFs after exposure
More informationPersistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment Bing Gong,, Michael Shelanski, Ottavio Arancio J Clin Invest. 2004;114(11):1624-1634. https://doi.org/10.1172/jci22831.
More informationNutrition and Water for Dementia Prevention
台日生技醫藥研討會 - 自然療法於失智症預防及照護之應用 Nutrition and Water for Dementia Prevention 胡朝榮 Chaur-Jong Hu, M.D. Professor and Direction, Department of Neurology and Dementia Center, Shuang Ho Hospital, Taipei Medical
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationHerpes Simplex Virus Type 1 and Alzheimer s disease:
The Neurodegenerates Herpes Simplex Virus Type 1 and Alzheimer s disease: Increasing Evidence for a major role of the virus 1 Introduction and Agenda 2 Agenda What is the HSV1 and why is it linked to AD?
More informationProlonged mitotic arrest induces a caspase-dependent DNA damage
SUPPLEMENTARY INFORMATION Prolonged mitotic arrest induces a caspase-dependent DNA damage response at telomeres that determines cell survival Karolina O. Hain, Didier J. Colin, Shubhra Rastogi, Lindsey
More informationDevelopment of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid
Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid Joanne ( 乔安妮 ) Mather Senior Scientist Waters Corporation Data courtesy of Erin Chambers and Mary
More informationThe effect of diets on neurodegenerative diseases
The effect of diets on neurodegenerative diseases Results from the FP7 project LIPIDIDIET A Kiliaan Donders Institute for Brain, Cognition and Behaviour, Centre for Neuroscience Dept Anatomy and dept Cognitive
More informationADNI PET CORE. Boston April Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price
ADNI PET CORE Boston April 27 Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price ADNI Florbetapir scan counts Number of Florbetapir scans N SMC EMCI LMCI AD Total
More informationThe AMBAR trial: an interim analysis ASFA Annual Meeting May 6, Palm Springs. CA. Antonio Páez, MD Senior Manager, Clinical Operations Grifols
The AMBAR trial: an interim analysis ASFA Annual Meeting May 6, 206. Palm Springs. CA Antonio Páez, MD Senior Manager, Clinical Operations Grifols A multicenter, randomized, controlled study to evaluate
More informationUNIVERSITY OF WESTERN ONTARIO
UNIVERSITY OF WESTERN ONTARIO Vladimir Hachinski, CM, MD, FRCPC, DSc Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada Vladimir.hachinski@lhsc.on.ca ALZHEIMER
More informationTBI: Translational Issues and Opportunities. Alan I Faden MD John Povlishock PhD
TBI: Translational Issues and Opportunities Alan I Faden MD John Povlishock PhD State of the Science: Translational Issues and Opportunities Translational Issues: Failed Clinical Trials - Animal Modeling
More informationKA Toulis, K. Dovas, M. Tsolaki. The endocrine facets of Alzheimer s disease and dementia-related disorders
KA Toulis, K. Dovas, M. Tsolaki The endocrine facets of Alzheimer s disease and dementia-related disorders Sex hormones Calcium metabolism GH/IGF-I Thyroid axis Metabolic hormones + dementia Sex hormones
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Efficacy and safety of amyloid-beta immunotherapy for Alzheimer's disease: systematic review Marwa El-toukhy, Mohamed Zalabia, Ahmed Raslan,
More informationHuman Neurology 3-Plex A
Human Neurology 3-Plex A SUMMARY AND EXPLANATION OF THE TEST The Human N3PA assay is a digital immunoassay for the quantitative determination of total Tau, Aβ42, and Aβ40 in human plasma and CSF. Determination
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationBaldeiras et al. Alzheimer's Research & Therapy (2018) 10:33
Baldeiras et al. Alzheimer's Research & Therapy (2018) 10:33 https://doi.org/10.1186/s13195-018-0362-2 RESEARCH Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the
More informationOverexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease Suzanne E. Wahrle,, Steven M. Paul, David M. Holtzman J Clin Invest. 2008;118(2):671-682. https://doi.org/10.1172/jci33622.
More informationIn 1906, the German physician Dr. Alois Alzheimer was the
With a new class of medication about to debut, an expert explains the rationale supporting the amyloid hypothesis. By Daniel D. Christensen, MD In 1906, the German physician Dr. Alois Alzheimer was the
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: patisiran_onpattro 11/2018 n/a 5/2019 2/2019 Description of Procedure or Service is a double-stranded small
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationMemory Care Monthly. Supporting Healthcare Professionals in Caring for the Aging November / December 2008
Memory Care Monthly Supporting Healthcare Professionals in Caring for the Aging November / December 2008 KEEP MEMORY ALIVE FOR THE COMING YEAR 2009 As the year comes to an end, we would like to remind
More informationParActin Research Summary
ParActin Research Summary (1) ParActin is useful for preventing memory loss in Alzheimer disease by activation of PPAR-γ Receptor. Juan L. Hancke. Instituto de Farmacologia, Universidad Austral de Chile,
More informationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer s Disease
original article Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer s Disease Rachelle S. Doody, M.D., Ph.D., Ronald G. Thomas, Ph.D., Martin Farlow, M.D., Takeshi Iwatsubo, M.D., Ph.D., Bruno
More informationSupplementary online data
THELANCETNEUROLOGY-D-07-00083 Supplementary online data MRI assessments MRI at each site included a volumetric spoiled gradient echo (T1-weighted) sequence with slice partition thickness of 1 5 mm or less
More informationSupplementary Figure 1
Supplementary Figure 1 AAV-GFP injection in the MEC of the mouse brain C57Bl/6 mice at 4 months of age were injected with AAV-GFP into the MEC and sacrificed at 7 days post injection (dpi). (a) Brains
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationTAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRKA INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, Carolyn Lai, Karen Duong-Polk, Amanda Tjitro,
More informationCerebral Small Vessel Disease and HAND in ARV-treated Subjects
Cerebral Small Vessel Disease and HAND in ARV-treated Subjects Cristian L. Achim, MD, PhD Ronald J. Ellis, MD, PhD Virawudh Soontornniyomkij, MD ARROW, Bucharest, Romania October 5-6, 2015 Rationale and
More informationMichael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center
Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Dementia an acquired syndrome consisting of a decline in memory and other cognitive functions Alzheimer s Disease Fronto temporal
More information